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Abstract
The main priority when designing cancer immuno-therapies has been to
seek viable biological mechanisms that lead to permanent cancer eradica-
tion or cancer control. Understanding the delicate balance between the role
of effector and memory cells on eliminating cancer cells remains an elusive
problem in immunology. Here we make an initial investigation into this
problem with the help of a mathematical model for oncolytic virotherapy;
although the model can in fact be made general enough to be applied also to
other immunological problems. Our results show that long-term cancer con-
trol is associated with a large number of persistent effector cells (irrespective
of the initial peak in effector cell numbers). However, this large number of
persistent effector cells is sustained by a relatively large number of memory
cells. Moreover, we show that cancer control from a dormant state cannot
be predicted by the size of the memory population.
Keywords: cancer modelling, effector and memory cells, tumour control,
cancer dormancy
1. Introduction1
It is well known that after successful reaction to a pathogen, long-lasting2
immunity can be stimulated [28]. Harnessing this natural defence system,3
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through the use of vaccines, has long been important in the fight against4
infections and diseases [3, 13]. More recently immune mechanisms have been5
employed to combat cancer through various immunotherapies such as viro-6
therapies, adoptive transfer of immune cells, cytokine therapies or antibody7
therapies. The low success rates of these immunotherapies is mainly caused8
by the fact that the immune-cancer interactions are still not fully understood.9
10
One of the emerging cancer therapies is oncolytic virotherapy, which in-11
volves both the direct action of tumour cell destruction by a virus (that12
usually carries tumour-associated antigens (TAAs)) and the indirect action13
of anti-tumour immunity (as the immune cells learn, through interaction14
with the virus, to recognise the TAAs)[24, 36, 39]. The interactions between15
the immune cells and the viruses lead to short term (or therapeutic) and16
long term (or prophylactic) immunity, which can be naively characterised17
by effector and memory immune cells, respectively [3]. In the short term18
effector cells act to eliminate a pathogen, while in the long-term memory19
cells act to prevent its reoccurrence. Memory cells are antigen-specific; they20
are stored after a pathogen has been eliminated [12, 25, 49] and are capable21
of generating new effector cells [40]. Successful cancer treatment protocols22
seek persistent protection against the tumour whether through permanent23
elimination or control.24
25
An important research question in immunology, still unanswered at this26
moment, refers to whether it is effector or memory cells which play the most27
important role in successful treatment protocols. It has been posited that28
multiple treatment protocols are likely to provide better success in immune29
therapies. In particular, for cancer therapies, multiple and subsequent treat-30
ments provide the possibility of activating the memory cells, which can then31
be used to generate a stronger more targeted response against the tumour32
[26, 43, 45, 53]. On the other hand, there is increasing evidence that long-33
term cancer control is accompanied by high numbers of effector cells [4, 7, 35].34
Understanding the delicate balance between the anti-tumour role of effector35
and memory cells will improve the existent anti-cancer treatments.36
37
Mathematical models (see, for example, [9, 15, 17, 23, 27, 33, 34, 38,38
44, 50, 51] and the references therein) have shown that possible outcomes for39
anti-tumour therapies are: tumour elimination, tumour dormancy, tumour40
escape or tumour control. A distinction between dormancy and control can41
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be made: tumour control occurs when the tumour is held permanently at42
a constant but relatively low size, while tumour dormancy is described as43
a prolonged period in which the tumour remains small and as such is both44
asymptomatic and undetectable but will at some stage grow again[37]. Al-45
though the nature of the biological mechanisms leading to tumour dormancy46
is not fully known [1, 42], one possible means is through tumour-immune47
interactions, so called immune-mediated dormancy [16, 41, 46]. It is thought48
that a constant interplay between the tumour and immune cells can lead to49
this temporary equilibrium, but eventually one population will overpower the50
other and either the tumour will “escape” and grow rapidly or it will be elim-51
inated [41, 47]. Clearly, from a clinical outlook tumour escape is a negative52
outcome and cancer elimination is the goal of any treatment protocol. How-53
ever, as we will discuss here (and as suggested before [20]), tumour control54
may be the only possible approach when tumour elimination is impossible.55
Tumour dormancy, although of short term therapeutic benefit, presents a56
clinical challenge in the long-term as predictions regarding its end stage (es-57
cape or elimination) may be unlikely.58
59
In this paper, we will introduce and investigate a mathematical model60
for oncolytic virotherapy, which allows us to study the balance between the61
memory and effector immune responses that can control tumour growth or62
lead to tumour dormancy. Although there are many mathematical mod-63
els for cancer virotherapies (see, for example, [5, 8, 18, 27, 44, 48, 52] and64
the references therein), the model investigated in this study is based on a65
more complex ODE model described in [15], which incorporated effector and66
memory immune responses and replicated a treatment protocol derived in67
[11]. In that protocol, two viruses that carried the same tumour-associated68
antigen (human dopachrome tautomerase, or hDCT) were administered 1469
days apart. The first virus, Adenovirus (Ad), acted as a vaccine virus by70
provoking an immune response against the tumour antigens. As this im-71
mune response receded, memory cells were created. The second virus, Vesi-72
cular Stomatitis Virus (VSV), was an oncolytic virus. This virus not only73
destroyed the cancer cells directly, but provoked a much stronger immune74
response to the tumour antigens due to the memory cells created in the first75
phase. The protocol, tested on mice, did not eradicate tumours in the major-76
ity of cases but did lead to improved survival times (compared with survival77
times for mice treated with just one virus). The mathematical model intro-78
duced in this study focuses on the second part of this treatment protocol,79
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i.e., on the oncolytic virus (injected after the formation of memory cells).80
Using this model, we will investigate how differences in the magnitude of the81
initial memory cell population lead to control, dormancy or escape of tumour82
cells. We will also determine the role of parameters governing the behaviour83
of effector cells on the outcome of the treatment.84
85
The paper is structured as follows. In Section 2 we describe the math-86
ematical model. In Section 3 we begin our investigation of the long-term87
dynamics of this model by focusing on the steady states and their stability.88
To get a better understanding of the balance between effector and memory89
immune responses, in Section 4 we discuss the steady-state behaviour of a90
simplified virus-free model. In fact, this simplified model is general enough91
to be applied to any immunotherapy and so may permit us to make stronger92
conclusions about the relative importance of different immune cell types in93
targeting cancer. In Section 5 we investigate numerically the long-term dy-94
namics of both the full model and the simplified model paying particular95
attention to the effects of varying the initial memory cell population size.96
Finally, in Section 6 we return to the simplified model and investigate the97
parameters that govern the effector cells. We conclude in Section 7 with a98
summary and discussion of the results.99
2. Model Description100
To model the tumour-immune-virus interactions, we focus on the fol-101
lowing populations: the uninfected (xu) and infected (xi) tumour cells, the102
memory (xm) and effector (xe) immune cells, and the virus particles (xv).We103
assume that the virus particles are VSV particles, and that the ef-104
fector/memory cells are CD8+ T cells. The equations below, which are105
adapted from [15], take into account the fact that effector cell proliferation106
is stimulated by both the presence of the free virus particles (as considered107
in [15]) and the uninfected tumour cells (an aspect not considered in [15]).108
Since the data in [11] ignored the spatial aspect of solid tumours,109
we decided to use an ODE model, with saturated interaction terms110
accounting for some of the tumour spatial structure.111
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dxu
dt
= rxu
(
1− xu + xi
k
)
− dv xu
hu + xu
xv − duxu xe
he + xe
, (1a)
dxi
dt
= dv
xu
hu + xu
xv − δxi − duxi xe
he + xe
, (1b)
dxm
dt
= pm
xv
hv + xv
xm
(
1− xm
M
)
, (1c)
dxe
dt
= pe
xv + xu
hv + xv + xu
xm − dexe − dtxuxe, (1d)
dxv
dt
= δbxi − ωxv. (1e)
These equations incorporate the following biological assumptions:112
• The uninfected tumour cells grow logistically at a rate r, up to their113
carrying capacity k. The carrying capacity is chosen specific-114
ally to correspond to the humane endpoint for experimental115
protocols with mice [11, 32] (see also Table A.2). In addi-116
tion, the large carrying capacity allows us to investigate the117
role of oncolytic therapy on large tumours [21]. Overall, this118
logistic term approximates the slow-down in tumour growth dynamics,119
following the lack of nutrients, as observed experimentally [30]. The120
uninfected tumour cells are infected by the virus particles at a rate dv,121
and are killed by the effector cells at a rate du. The saturated form122
of the tumour-virus interaction term accounts in part for the123
spatial structure of the tumour, which leads to reduced inter-124
actions between the tumour cells and viruses (studies showing125
that viruses usually infect only a small number of tumour cells126
[10]). Finally, the saturated form of the tumour-immune in-127
teraction term accounts for the reduced number of activated128
immune cells that reach and interact with the tumour cells129
[19].130
• The infected tumour cells die at a rate δ (when they burst to let the131
replicated virus particles out). Also, they are killed by the effector cells132
at a rate du.133
• The memory cells proliferate, at a rate pm, in the presence of virus134
particles (virus antigens). These cells have a carrying capacity M ,135
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which models the competition for space between memory cells or com-136
petition for antigens [2]. We assume here that the memory cells persist137
for a very long time (compared to the effector and tumour cells), and138
thus we ignore their natural death rate. Parameter hv denotes the139
half-concentration of viral antigens that trigger the memory response.140
The saturated form of the virus-induced memory response ac-141
counts for the limited proliferation of memory cells in response142
to virus particles.143
• The effector cells are the result of de-differentiation of memory cells144
in the presence of antigens (both virus antigens and tumour antigens).145
The de-differentiation rate is pe. These effector cells have a natural146
death rate of de, and can be inactivated by the tumour cells at a rate147
dt. For simplicity, we decided to use the same half-concentration hv148
for the antigens (both viral and tumour antigens). However, as we will149
discuss in Section 6, the magnitude of this parameter does not have a150
great influence on the dynamics.151
• The virus particles are produced by the infected tumour cells at a rate152
δb, where δ is the death rate of infected cells and b is the burst size (i.e.,153
the number of particles inside an infected cell). Finally, these particles154
are eliminated by the body at a rate ω.155
For a more detailed description of the model, see [15]. Note that156
the 2-compartment model in [15] accounted for the delay in the157
effector immune response following virus stimulation. To gain a158
better understanding of the key parameters in tumour-immune-159
virus dynamics, in this paper we decided to ignore such a delay.160
We emphasise that many of the biological processes considered161
in this mathematical model could have been formulated differently162
(see the models in [5, 8, 14, 15, 18, 27, 44, 48, 52]). For example, the163
proliferation of memory cells following virus stimulation was im-164
plemented differently in a previous study [15], which considered a165
different pathway for memory differentiation - one of the multiple166
pathways suggested in the literature [22]. Equally, the tumour-167
immune and tumour-virus interactions could have been modelled168
using bi-linear terms, rather than the saturated forms we give, and169
the tumour growth could have been modelled using a Gompertzian170
or exponential form [6, 27, 31]. However, it is not the goal of this171
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paper to investigate the impact of the different possible descrip-172
tions of interaction terms on the outcomes of the model. Rather, it173
is to choose an example of interaction terms and use them to take174
a first look at the potential importance of effector versus memory175
cells during viral therapies.176
3. Steady States and Stability177
We start the investigation of model (1) by studying first its long-term178
dynamics. To this end, we identify all possible steady states and determine179
their stability. The parameter values investigated in this article (also involved180
in the stability of these steady states) are summarised in Appendix A. Note181
that these values apply to tumour-immune interactions observed in mice.182
Tumour-Free Steady States (TF). The tumour-free steady states are given183
by (0, 0, x∗m, 0, 0). These steady states are always unstable saddles, due to184
one positive eigenvalue λ1 = r > 0. As such, this model predicts that the185
treatment protocol cannot lead to permanent tumour elimination. Thus, in186
the following, we will be concerned with investigating stable tumour-present187
steady states for which the tumour size is considered to be under control,188
i.e. below a certain threshold. For the purpose of this study, we will assume189
that the value of this threshold is 106 cells (which is the initial value for the190
number of cancer cells xu(0)).191
Tumour-Present, Virus-Present, Immune-Free Steady State (IF) . The single192
immune-free steady state is given by (x∗u, x
∗
i , 0, 0, x
∗
v) where193
x∗u =
ωhu
bdv − ω , x
∗
i =
k − x∗u
1 +
δk
rx∗u
and x∗v =
δb
ω
 k − x∗u
1 +
δk
rx∗u
 . (2)
This steady state is identical to the immune-free steady state for the model194
introduced in [15]. It can be easily shown (omitted here) that this state is195
always unstable and as such we do not consider it further.196
Tumour-Present, Virus-Free Steady States (VF) . For model (1), there are197
multiple virus-free steady states (in fact, infinitely many). We can gain in-198
sight into these steady states by plotting the surfaces described by the right-199
handside of Equations (1a) and (1d) for xm, xe and xu (since xv = xi = 0, it200
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means that the remaining equations are satisfied trivially). In Figure 1 we201
show the intersections of these two surfaces, corresponding to the virus-free202
steady states of the system. Two sets of steady states satisfy these intersec-203
tion curves: the tumour-free (TF) steady states (i.e., xu = xe = 0, xm ∈ R,204
which have already been discussed above) and the tumour-present steady205
states (VF), which we focus on next. We observe that for the tumour-present206
states, the size of the tumour ranges from low (non-zero) values, which cor-207
respond to tumour being controlled by the immune system, to very large208
values (the carrying capacity size, k). To achieve a low steady state tumour-209
size there must be sufficiently high accompanying memory and effector cell210
populations.211
TF Steady States
VF Steady States
u
x*
e
x*mx*
Figure 1: A plot showing the possible virus-free steady states of system (1). The tumour-
free (TF) states are given by the green thick line, the tumour-present virus-free (VF) states
are given by the blue curve.
212
Further insight can be gleaned by considering analytic solutions to Equa-213
tions (1a) and (1d). In the following we denote the steady states of xu, xm214
and xe by x
∗
u, x
∗
m and x
∗
e, respectively. From Equation (1d), we can obtain215
an expression for x∗e in terms of x
∗
u and x
∗
m, which is given as216
x∗e =
pex
∗
m
x∗u
hv + x∗u
de + dtx∗u
. (3)
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Substituting this expression into Equation (1a) and considering only the217
tumour-present solutions yields the cubic equation218
A(x∗u)
3 + (B + Cx∗m)(x
∗
u)
2 + (D + Ex∗m)x
∗
u − F = 0, (4)
where219
A = rdthe, B = rhe (de + dthv − dtk) , C = rpe,
D = rhe (dehv − dthvk − dek) , E = kpe(du − r) and F = rkhedehv. (5)
Only real positive solutions of the cubic provide biologically relevant steady220
states. For any given x∗m we may have between one and three steady states x
∗
u.221
222
To investigate the stability of these tumour-present virus-free steady state223
(x∗u, 0, x
∗
m, x
∗
e, 0), we observe that the five eigenvalues of the Jacobian calcu-224
lated at the steady states are: λ = 0 and the two solutions of the quadratics225
λ2 +G1,2λ+H1,2 = 0, (6)
where
G1 = ω + δ + du
x∗e
he + x∗e
, (7a)
H1 = ω
(
δ + du
x∗e
he + x∗e
)
− δbdv x
∗
u
hu + x∗u
, (7b)
and
G2 =
2rx∗u
k
+ du
x∗e
he + x∗e
− r + de + dtx∗u, (8a)
H2 =(de+ dtx
∗
u)
(
2rx∗u
k
+ du
x∗e
he + x∗e
− r
)
+
duhex
∗
u
(he + x∗e)2
(
pehv
(hv + x∗u)2
x∗m − dtx∗e
)
. (8b)
Positive eigenvalues exist, and stability fails if either H1 < 0 or H2 < 0226
(or both). In Figure 2 we plot the states x∗u against the states x
∗
m given227
by the cubic (4), for the parameter values investigated in this article (see228
Table A.2). Here, we show also the threshold stability curves, H1 = 0 and229
H2 = 0. We note that only one branch of stable steady state solutions exists.230
Such states are characterised by a low (controlled) tumour size accompanied231
by a persistent memory cell population.232
9
2Stable S.S.
Unstable S.S.
H  = 0
H  = 01
m
*
x *
u
x
[L
og
 Sc
ale
]
Figure 2: Plots of the steady state tumour sizes x∗u against the the steady state memory
size x∗m. To show clearly what happens for small as well as large tumour sizes, we use
a log scale for x∗u. Stable steady states are indicated by blue circles and unstable states
by black squares. We also plot the curves H1 = 0 and H2 = 0 in red (solid and dashed
respectively), to indicate the boundaries which mark a change in stability.
Tumour-Present, Virus-Present, Immune-Present Steady State (TVI). If all233
populations exist, the right-hand side of Equation (1c) implies xm = M . In234
Figure 3 we plot the intersection curves of the surfaces given by the right-235
hand side of Equations (1a), (1b) and (1d), in terms of the steady state236
populations, x∗u, x
∗
v and x
∗
e (using xm = M and replacing xi with ωx
∗
v/δb,237
determined from the right-hand side of Equation (1e)). We observe that there238
are only two distinct biologically relevant intersections of all three surfaces239
corresponding to steady states of model (1). Neither of these states, namely240
the TF steady state (xu = xv = 0) and a VF steady state (xu ≈ 221,241
xm = M = 10
4, xe ≈ 864), has all five populations present. Thus, at least242
for the parameter values investigated in this article (see Appendix A), a TVI243
state does not exist and as such we should concern ourselves with stabilising,244
at a low tumour size, the virus-free (VF) steady states discussed previously.245
Biologically, our concern with this VF state makes sense, as we would hope246
to find a treatment protocol in which, after reducing the tumour size, the247
virus would be cleared.248
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given by Eqs. (1a) and (1b)
Steady States
x*u
x* x*v e
VF
TF
Intersections of the surfaces
given by Eqs. (1a) and (1d)
Intersections of the surfaces 
Figure 3: A plot showing the intersections of surfaces described by equations (1a), (1b)
and (1d). Circled are the possible steady states for model (1), when xm = M .
4. A simplified virus-free system249
Next, we consider a completely virus-free system. We will return to this
model in the next sections, when we will investigate the role of the memory
versus effector immune responses in tumour control. In the absence of the
virus, system (1) reduces to
dxu
dt
= rxu
(
1− xu
k
)
− duxu xe
he + xe
, (9a)
dxm
dt
= 0, (9b)
dxe
dt
= pe
xu
hv + xu
xm − dexe − dtxuxe. (9c)
The steady states (x∗u, x
∗
m, x
∗
e) of this system still satisfy equations (3) and250
(4). We note from equation (9b) that the memory cell population does not251
change and as such will remain at its initial size. Thus, we may consider252
x∗m = xm(0). Therefore, the solutions for x
∗
u obtained by solving (4) depend253
directly on the initial memory cell population size.254
255
The eigenvalues of system (9) are governed by256
λ(λ2 +G2λ+H2) = 0, (10)
where G2 and H2 are given as before. Thus, stability of the virus-free system257
is governed solely by the sign of H2. In Figure 4 we plot the steady state258
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tumour sizes, x∗u, against the steady state memory size, x
∗
m (as in Figure 2,259
but now with only the H2 = 0 stability boundary). We observe that for260
a range of x∗m values (x
∗
m ≈ 230 − 460) the system is bistable. However,261
investigation of the long-term behaviour of system (9) shows that the system262
always chooses one stable steady state (filled blue circles in Figure 4(a)).263
We observe that the transition from the upper stable branch to the lower264
stable branch occurs as the maximum tumour size crosses the unstable branch265
(described by black squares). Hence, the unstable branch of steady states266
x∗u acts as a separatrix: if the solution for xu reaches any point above this267
branch the dynamics will approach the upper stable steady state; on the268
other hand, if the solution remains below this branch, the dynamics will269
approach the lower stable steady state. To indicate this, we also include the270
maximum tumour sizes attained for each xm(0) = x
∗
m in Figure 4 (see red271
crosses).272
2
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Figure 4: Plot of the steady state tumour sizes x∗u against the the steady state memory
sizes x∗m = xm(0). To show more clearly what happens for small and large tumour sizes,
we use a log scale for x∗u. Stable steady states are indicated by blue circles and unstable
by black squares. The dynamics of the system evolves towards the filled blue circles.
We also include the curve H2 = 0 (red dashed curve) to indicate the boundary which
marks a change in stability and the maximum tumour size (red crosses) attained for each
xm(0) = x
∗
m.
273
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5. Tumour growth dynamics274
In this section, we investigate the time-evolution of systems (9) and (1)275
towards the VF steady states described previously.276
Figure 5: Explicit time plots for (a) the uninfected tumour size, (b) the effector population
for different values of the initial memory cell-population for virus-free initial conditions. In
each case xu(0) = 10
6 and xv(0) = xi(0) = xe(0) = 0. All parameters are as in Table A.2.
277
We start by discussing first the dynamics of the virus-free system (9). In278
Figure 5 we plot: (a) the explicit time behaviour of the tumour population,279
and (b) the explicit time behaviour of the effector population, for different280
values of the initial memory cell population xm(0). (The initial conditions281
for the other variables are xu(0) = 10
6, xe(0) = xv(0) = xi(0) = 0.) This plot282
corresponds directly with the behaviour predicted by Figure 4: increasing the283
initial memory cell population leads to a lower steady state for the tumour284
size and a higher steady state for the effector population size. A substantial285
jump in tumour/effector size occurs between xm(0) = 348 and xm(0) = 349.286
When xm(0) = 348 we observe a period of cancer dormancy (corresponding287
to a sustained “high” effector population size), between t = 10 and t = 60288
days. However, the tumour begins to grow again and achieves a high steady-289
state size. When xm(0) = 349 the system appears similarly dormant, but290
then tends to a much lower steady-state tumour size (low enough to be con-291
sidered under control). When the steady state for the tumour population is292
on the lower branch of the stable solutions shown in Figure 4, the effector293
population always tends towards the steady state x∗e ≈ 864 cells.294
295
Note that the behaviour shown in Figure 5 is for initial conditions with296
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zero effector cells (xe(0) = 0). If we add an initial effector cell population to297
the system, it has the effect of slightly reducing the value of xm(0) for which298
we achieve the jump to the lower steady-state branch for the tumour cells.299
For example, if xe(0) = 100 we require xm(0) ≥ 323 to achieve the lower300
value of x∗u.301
Figure 6: Explicit time plots for (a) the uninfected tumour size, (b) the effector population
for different values of the initial memory cell-population for virus-present initial conditions.
In each case xu(0) = 10
6, xv(0) = 1 and xi(0) = xe(0) = 0. All parameters are as in
Table A.2.
302
We next consider the behaviour of the full system (1) (which is not virus-303
free, but evolves towards a virus-free steady state over time), as we vary the304
initial memory cell population. In Figure 6 we plot (a) the explicit time be-305
haviour of the tumour population, and (b) the explicit time behaviour of the306
effector population, for different values of the initial memory cell population307
xm(0). In Figure 6(a) we observe that introducing a single virus particle308
reduces the tumour size to a low and controlled steady state, for all values309
of xm(0). Figure 2 predicted that only low tumour sizes for VF states were310
stable. Note that for low xm(0) values, the tumour first grows towards a311
very large “fatal” size, before decaying to a low steady-state value. Thus, as312
we vary xm(0), it becomes important to consider not only the steady state313
tumour size but also the maximum tumour size. Figure 6(b) shows that in314
each case the effector population tends to x∗e ≈ 864.315
316
Unexpected dynamics can be seen in the inset to Figure 6(a): increasing317
xm(0) leads to an increase in the steady-state x
∗
u. To get a better understand-318
ing of why this happens, in Figure 7 we plot both the maximum tumour319
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size and the steady-state tumour size against the initial memory popula-320
tion size xm(0), for xv(0) = {1, 102, 104, 106}. As observed in Figure 7(a),321
when we introduce one virus particle, a low initial memory population gives322
rise to a low steady-state tumour size. However, this behaviour is also ac-323
companied by a higher peak in the tumour size. As we increase xm(0),324
the maximum tumour size decreases while the steady-state value for the tu-325
mour increases. This increasing/decreasing behaviour becomes particularly326
strong for xm(0) ∈ (340, 350). Note that for xm(0) > 430, the maximum327
tumour sizes and the steady-state tumour sizes are below the thresholds of328
107 and 106 cells, respectively. These thresholds are sufficiently low to en-329
sure the survival of the mice. In Figure 7(b) (where xv(0) = 10
2), the sharp330
changes in both the maximum tumour size and the steady-state size are no331
longer observed. Instead both profiles are continuous and the steady-state332
size achieves a much lower peak. As we increase the initial virus population333
further (see Figure 7(c)), the maximum tumour size reduces more rapidly,334
while the steady-state tumour size remains almost constant at x∗u ≈ 221335
cells, far below the threshold of 106 cells. We do note, however, that even336
when xv(0) = 10
6 and there is a high initial memory population size (see337
Figure 7(d)), the peak of the tumour size is above 106 cells (although the338
attained size is short-lived and not typically fatal).339
6. Memory versus immune responses on tumour growth340
To compare the importance of the memory versus immune responses in tu-341
mour elimination, we focus on the simplified virus-free system. In Figure 8,342
we graph the steady states x∗u against the steady states x
∗
m (equivalent to343
the initial memory population in this case) along with the stability bound-344
ary H2 = 0, while changing different parameters that control the effector345
immune response. In Figure 8(a) we change the rate pe that controls the de-346
differentiation of memory cells into effector cells. Increasing this rate reduces347
the required initial memory size to achieve a lower steady-state tumour size.348
Decreasing the the natural effector decay rate de (see Figure 8(b)) also leads349
to a reduction in the initial memory size required to achieve a lower steady-350
state tumour size. Similar results are obtained when decreasing the effector351
half-saturation constant he (see Figure 8(c)). In Figure 8(d) we include a352
plot which shows the effect of changing hv. We see here that there are almost353
no differences in the long-term behaviour of system (1) when 1 < hv < 10
4.354
However, for hv = 10
6 there are small differences in the size of x∗u approached355
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Figure 7: Plots of the maximum tumour size (black dashed-dot curve) and the steady-state
tumour size (red dashed curve), for different values of the initial virus population. The
parameter values are as in Table A.2.
by system (1), for initial memory population sizes x∗m ∈ (200, 450).356
357
We observed above (see Figures 5 for the virus-free system and Figure358
6 for the virus-present system) that a low steady-state tumour size was ac-359
companied by an effector steady-state size of x∗e ≈ 864 cells. To achieve this360
steady-state effector population size we must either have a high enough ini-361
tial memory population or, as shown in Figure 8, be able to control immune-362
related parameters i.e., provoke a higher de-differentiation of memory cells363
to effector cells, reduce the effector cell natural decay and enhance effector-364
tumour interactions. However, it might not be possible to control these365
parameters experimentally. And even if we can alter them favourably, a366
higher initial memory population size continues to be important. As such,367
we conclude that focus should remain on stimulating a high initial memory368
population.369
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Figure 8: Plots showing the steady state behaviour (solid curves) of the virus-free system
along with stability boundaries H2 = 0 (dashed curves) for different parameters. In panel
(a) we change pe, in panel (b) we change de, in panel (c) we change he and in panel (d)
we change hv, while keeping all other parameters fixed as in Table A.2.
7. Discussion370
In this article, we introduced a simple, nonlinear mathematical model371
that described the interactions among immune cells, cancer cells and viruses.372
Although the original purpose of the model was to investigate the dynam-373
ics of oncolytic therapy, much of what we have shown applies to a model374
of a virus-free system. As such, the model could be used to give insight375
into immune-cancer interactions after the stimulation of anti-cancer immune376
memory cells. We focussed our attention on the importance of memory377
and effector cell population sizes on stabilising the tumour-present virus-free378
steady states.379
380
We found that for our model (system (1)) the dynamic behaviour al-381
ways evolved towards a tumour-present virus-free steady state, whether un-382
der virus-free or virus-present initial conditions. When the system was fully383
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virus-free, we found that only by increasing the initial memory cell popula-384
tion could we achieve reduced tumour growth and low steady-state tumour385
size. For the virus-present system, it was important to have a high initial386
memory cell population in order to reduce the initial growth (and maximum387
size) of the tumour (although there was a slight trade-off as the steady-state388
size increased as we increased xm(0)). Having a high initial memory cell389
population became less important as we increased the initial virus popula-390
tion, xv(0). Indeed when xv(0) = 10
6 there was very little difference in the391
maximum tumour size and no difference in the steady-state tumour size,392
for all values of xm(0). A parameter investigation showed that provoking a393
high initial memory population would always lead to a positive outcome, and394
that biologically this is likely to be more attainable than stimulating changes395
to the immune-related parameters. Importantly, we have found that low396
steady-state tumour sizes were always accompanied by a high steady state397
effector population (always around x∗e ≈ 864 cells). As such, this adds to the398
evidence that suggests that cancer control is the result of a persisting popu-399
lation of effector cells, regardless of the initial number immune cells [4, 35, 7].400
401
Our investigations also indicated that specific conditions could lead to402
immune-mediated cancer dormancy. It is now evident from the literature403
that cancers may remain dormant for prolonged periods of time, after which404
tumours will either escape (and grow excessively) or be eliminated. Here,405
we showed that very slight changes to the system set-up (in our case slight406
changes to the initial memory cell population) could lead to a change between407
these two contrasting outcomes. Furthermore, with a wide range of paramet-408
ers it is unlikely that we could predict whether the patient would go on to409
experience cancer growth or cancer reduction and control after dormancy.410
Unfortunately due to the very nature of cancer dormancy (i.e., cancer is at411
a very small size), it is often elusive to the methods of detection currently412
available to clinicians. Our findings remind us that it remains of great im-413
portance to search for ways to detect and monitor cancer dormancy.414
415
Having discussed our results, we wish to stress that they are sub-416
ject to the limitations of our model. As mentioned, when discussing417
the model set up, there are alternative ways of incorporating the418
biological mechanisms known to occur, and equally we have only419
attempted to describe certain biological pathways which are still420
not fully understood. Different formulations of the model could421
18
well provide further insight into the role of effector and memory422
cells; in fact the subject may benefit from a detailed investigation423
of general interaction terms. However, our investigation into this424
important immunological problem aims to be a starting point for425
further discussion on this topic.426
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Appendix A. Appendices430
Variables Meaning Initial Value
xu uninfected cancer cells 10
6
xi infected cancer cells 0
xm memory cells 1− 104
xe effector cells 0
xv virus particles 0− 106
Table A.1: Initial values of the variables for the model given by Equations (1a)-(1e).
References431
[1] Almog, N., 2010. Molecular mechanisms underlying tumor dormancy.432
Cancer Lett. 294 (2), 139–46.433
[2] Antia, R., Pilyugin, S., Ahmed, R., 1998. Models of immune memory:434
On the role of cross-reactive stimulation, competition, and homeostasis435
in maintaining immune memory. Proc. Natl. Acad. Sci. USA.436
[3] Bachmann, M. F., Jennings, G. T., Nov 2010. Vaccine delivery: a matter437
of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol.438
10 (11), 787–96.439
[4] Baitsch, L., Baumgaertner, P., Deveˆvre, E., Raghav, S. K., Legat, A.,440
Barba, L., Wieckowski, S., Bouzourene, H., Deplancke, B., Romero, P.,441
Rufer, N., Speiser, D. E., Jun 2011. Exhaustion of tumor-specific cd8442
t cells in metastases from melanoma patients. J. Clin. Invest. 121 (6),443
2350–60.444
19
Parameter Value Units Description & Reference
r 0.927 days−1 proliferation rate for tumour cells [11]
k 1.8182× 108 cells/vol carrying capacity for the tumour cells
dv 0.0038 (cells/vol)(PFU/vol)
−1(days)−1 infection rate of tumour cells with the oncolytic
virus
du 2.0 days
−1 lysis rate of tumour cells (infected and uninfec-
ted) by the immune cells [29]
hu 1 cells/vol half-saturation constant for the tumour cells in-
fected with the oncolytic virus
he 10
3 cells/vol half-saturation constant for the effector cells
that support half the maximum killing rate
hv 10
4 PFU/vol half-saturation constant of (viral & tumour)
antigens that induce half the maximum pro-
liferation rate of immune cells
δ 1 days−1 rate at which the oncolytic virus kills the tumor
cells
pm 2.5 days
−1 proliferation rate of memory cells following sec-
ondary encounter with tumor antigens carried
by virus particles [11]
M 104 (cells)/vol carrying capacity for memory cells
pe 0.4 days
−1 rate at which memory cells become effector
cells following secondary encounter with tumor
antigens carried by virus particles
de 0.1 days
−1 death rate of effector cells [11]
dt 5× 10−9 (cells)−1(vol)(days)−1 inactivation rate of immune effector cells by the
tumor cells
ω 2.042 days−1 decay rate for the concentration of oncolytic
virus (VSV) particles in the blood
b 1000 (PFU/vol)(cell)−1(vol) number of virus (VSV) particles released from
an infected cell, capable of forming plaques
Table A.2: Parameters of model used throughout and values used for numerical simula-
tions. In each case they are as given in [15] (or at least within the ranges given). Through-
out this report, we consider the density of cells (i.e., cell numbers per blood volume (vol))
and the plaque-forming units (PFU) for the virus particles. (PFU is a generally accep-
ted functional measurement for the virus particles; defective viruses which do not form a
plaque cannot infect their target and are discounted.)
[5] Bajzer, Z., Carr, T., Josic´, K., Russell, S., Dingli, D., 2008. Modeling445
of cancer virotherapy with recombinant measles viruses. J. Theor. Biol.446
252, 109–122.447
[6] Benzekry, S., Lamont, C., Beheshti, A., Tracz, A., Ebos, J. M. L.,448
Hlatky, L., Hahnfeldt, P., Aug 2014. Classical mathematical models for449
description and prediction of experimental tumor growth. PLoS Comput450
Biol 10 (8), e1003800.451
[7] Berezhnoy, A., Rajagopalan, A., Gilboa, E., 2014. A clinically useful452
20
approach to enhance immunological memory and antitumor immunity.453
OncoImmunology 3, e28811.454
[8] Biesecker, M., Kimn, J.-H., Lu, H., Dingli, D., Bajzer, Z., 2010. Optim-455
ization of virotherapy for cancer. Bull Math Biol 72 (2), 469–89.456
[9] Bozic, I., Allen, B., Nowak, M. A., 2012. Dynamics of targeted cancer457
therapy. Trends Mol. Med. 18, 311–316.458
[10] Breitbach, C., Paterson, J., Lemay, C., Falls, T., McGuire, A., Par-459
ato, K., Stojdl, D., Daneshmand, M., Speth, K., Kirn, D., McCart,460
J., Atkins, H., Bell, J., 2007. Targeted inflammation during oncolytic461
virus therapy severely compromises tumor blood flow. Molecular Ther-462
apy 15 (9), 1686–93.463
[11] Bridle, B., Stephenson, K., Boudreau, J., Koshy, S., Kazdhan, N., Pul-464
lenayegum, E., Brunellie`re, J., Bramson, J., Lichty, B., Wan, Y., 2010.465
Potentiating cancer immunotherapy using an oncolytic virus. Mol. Ther.466
18, 1430–1439.467
[12] Crotty, S., Ahmed, R., 2004. Immunological memory in humans. Semin.468
Immunol. 16, 197–203.469
[13] Dermime, S., Armstrong, A., Hawkins, R., Stern, P., 2002. Cancer vac-470
cines and immunotherapy. Brit. Med. Bull. 62, 149–162.471
[14] Eftimie, R., Bramson, J. L., Earn, D. J. D., 2011. Interactions between472
the immune system and cancer: a brief review of non-spatial mathem-473
atical models. Bull Math Biol 73 (1), 2–32.474
[15] Eftimie, R., Dushoff, J., Bridle, B., Bramson, J., Earn, D., 2011. Multi-475
stability and multi-instability phenomena in a mathematical model of476
tumor-immune-virus interactions. Bull. Math. Biol. 73 (12), 2932–2961.477
[16] Farrar, J., Katz, K., Windsor, J., Thrush, G., Scheuermann, R., Uhr,478
J., Street, N., 1999. Cancer dormancy. VII. A regulatory role for CD8+479
T cells and IFN-γ in establishing and maintaining the tumour-dormant480
state. J. Immunol. 162, 2842–2849.481
[17] Ferreira Jr., S. C., Martinsa, M. L., Vilela, M. J., 2005. Fighting cancer482
with viruses. Physica A 345, 591–602.483
21
[18] Friedman, A., Tian, J., Fulci, G., Chiocca, E., Wang, J., 2006. Glioma484
virotherapy: effects of innate immune suppression and increased viral485
replication capacity. Cancer Res. 66 (4), 2314–2319.486
[19] Gajewski, T., Schreiber, H., Fu, Y.-X., 2013. Innate and adaptive im-487
mune cells in the tumor microenvironment. Nature Immunology 14 (10),488
1014–22.489
[20] Gatenby, R., 2009. A change of strategy in the war on cancer. Nature490
459, 509–509.491
[21] Ikeda, K., Ichikawa, T., Wakimoto, H., Silver, J., Deisboeck, T., Finkel-492
stein, D., Harsh IV, G., Louis, D., Bartus, R., Hochberg, F., Chiocca, E.,493
1999. Oncolytic virus therapy of multiple tumors in the brain requires494
suppression of innate and elicited antiviral responses. Nature Medicine495
5 (8), 881–887.496
[22] Kaech, S., Wherry, J., Ahmed, R., 2002. Effector and memory t-cell497
differentiation: implications for vaccine development. Nature Reviews498
Immunology 2, 251–262.499
[23] Karev, G. P., Novozhilov, A. S., Koonin, E. V., 2006. Mathematical500
modeling of tumor therapy with oncolytic viruses: effects of parametric501
heterogeneity on cell dynamics. Biol. Direct. 1, 30.502
[24] Kelly, E., Russell, S. J., 2007. History of oncolytic viruses: Genesis to503
genetic engineering. Mol. Ther. 15, 651–659.504
[25] Klebanoff, C. A., Gattinoni, L., Restifo, N. P., 2006. CD8+ T-cell505
memory in tumor immunology and immunotherapy. Immunol. Rev. 211,506
214–224.507
[26] Klebanoff, C. A., Gattinoni, L., Torabi-Parizi, P., Kerstann, K.,508
Cardones, A. R., Finkelstein, S. E., Palmer, D. C., Antony, P. A.,509
Hwang, S. T., Rosenberg, S. A., Waldmann, T. A., Restifo, N. P., 2005.510
Central memory self tumor-reactive CD8+ T cells confer superior an-511
titumor immunity compared with effector memory T cells. PNAS 102,512
9571–9576.513
[27] Komarova, N. L., Wodarz, D., 2010. Ode models for oncolytic virus514
dynamics. J. Theor. Biol. 263 (4), 530–43.515
22
[28] Kumar, H., Kawai, T., Akira, S., 2011. Pathogen recognition by the516
innate immune system. Int. Rev. Immunol. 30 (1), 16–34.517
[29] Ku¨ndig, T., Bachmann, M., Oehen, S., Hoffmann, U., Simard, J., Kal-518
berer, C., Pircher, H., Ohashi, P., Hengartner, H., Zinkernagel, R., 1996.519
On the role of antigen maintaining cytotoxic T-cell memory. Proc. Natl.520
Acad. Sci. USA 93, 9716–9723.521
[30] Laird, A., 1964. Dynamics of tumor growth. Br. J. Cancer 18, 490–502.522
[31] Marusic´, M., M., Vuk-Pavlovic, S., 1993. Prediction power of mathem-523
atical models for tumour growth. Journal of Biological Systems 1 (1),524
69–78.525
[32] N.I.H., O.A.C.U., 1996. Guidelines for endpoints in animal study propos-526
als. http://oacu.od.nih.gov/ARAC/documents/ASP Endpoints.pdf.527
[33] Paiva, L. R., Binny, C., Ferreira, Jr., S. C., Martins, M. L., February528
2009. A multiscale mathematical model for oncolytic virotherapy. Can-529
cer Res. 69.530
[34] Paiva, L. R., Martins, M. L., Ferreira, Jr., S. C., 2011. Questing for an531
optimal, universal viral agent for oncolytic virotherapy. Physical Review532
E 84.533
[35] Paulis, L., Mandal, S., Kreutz, M., Figdor, C., 2013. Dendritic cell-based534
nanovaccines for cancer immunotherapy. Curr. Opp. Immunol. 25, 389–535
395.536
[36] Pol, J. G., Resse´guier, J., Lichty, B. D., 2012. Oncolytic viruses: a step537
into cancer immunotherapy. Virus Adapt. and Treat. 4, 1–21.538
[37] Quesnel, B., 2008. Dormant tumor cells as therapeutic target? Cancer539
Lett. 267, 10–17.540
[38] Rommelfanger, D. M., Offord, C. P., Dev, J., Bajzer, Z., Vile, R. G.,541
Dingli, D., 2012. Dynamics of melanoma tumor therapy with vesicular542
stomatitis virus: explaining the variability in outcomes using mathem-543
atical modeling. Gene. Ther. 19 (5), 543–9.544
[39] Russell, S. J., Peng, K.-W., Bell, J. C., 2012. Oncolytic virotherapy.545
Nat. Biotechnol. 30 (7), 658–70.546
23
[40] Sallusto, F., Geginat, J., Lanzavecchia, A., 2004. Central memory and547
effector memory t cell subsets: function, generation, and maintenance.548
Annu. Rev. Immunol. 22, 745–763.549
[41] Teng, M., Swann, J., Koebel, C., Schreiber, R., Smyth, M., 2008.550
Immune-mediated dormancy: an equilibrium with cancer. J. Leukoc.551
Biol. 84, 988–993.552
[42] Uhr, J., Pantel, K., 2011. Controversies in clinical cancer dormancy.553
Proc. Natl. Acad. Sci. USA 108, 12396–12400.554
[43] van Duikeren, S., Fransen, M. F., Redeker, A., Wieles, B., Platenburg,555
G., Krebber, W.-J., Ossendorp, F., Melief, C. J. M., Arens, R., 2012.556
Vaccine-induced effector-memory cd8+ t cell responses predict thera-557
peutic efficacy against tumors. J. Immunol. 189 (7), 3397–403.558
[44] Wein, L. M., Wu, J. T., Kirn, D., 2003. Validation and analysis of559
a mathematical model of a replication-competent oncolytic virus for560
cancer treatment: Implications for virus design and delivery. Cancer561
Res. 63, 1317–1324.562
[45] Wherry, J. E., Ahmed, R., 2004. Memory cd8 t-cell differentiation during563
viral infection. J. Virol. 78 (11), 5535–45.564
[46] Wilkie, K., Hahnfeldt, P., 2013. Mathematical models of immune-565
induced cancer dormancy and the emergence of immune evasion. In-566
terface Focus 3, 20130010.567
[47] Wilkie, K., Hahnfeldt, P., 2013. Tumorimmune dynamics regulated in568
the microenvironment inform the transient nature of immune-induced569
tumor dormancy. Cancer Res. 3, 3534–3544.570
[48] Wodarz, D., 2001. Viruses as antitumor weapons: defining conditions571
for tumor remission. Cancer Res. 61, 3501–3507.572
[49] Wodarz, D., 2006. Killer Cell Dynamics: Mathematical and Computa-573
tional Approaches to Immunology. Springer.574
[50] Wodarz, D., Hofacre, A., Lau, J. W., Sun, Z., Fan, H., Komarova,575
N. L., 2012. Complex spatial dynamics of oncolytic viruses in vitro:576
mathematical and experimental approaches. PLoS Comput. Biol. 8 (6),577
e1002547.578
24
[51] Wodarz, D., Komarova, N., 2009. Towards predictive computational579
models of oncolytic virus therapy: basis for experimental validation and580
model selection. PLoS One 4 (1), e4271.581
[52] Wu, J., Kirn, D., Wein, L., 2004. Analysis of a three-way race between582
tumor growth, a replication-competent virus and an immune response.583
Bull. Math. Biol. 66 (4), 605–625.584
[53] Zhang, P., Coˆte`, A. L., de Vries, V. C., Usherwood, E. J., Turk, M. J.,585
2007. Induction of postsurgical tumor immunity and t-cell memory by586
a poorly immunogenic tumor. Cancer Res. 67, 6468–6477.587
25
